Letter to the Editor
To the editor: We read with interest the article by Esposito et al 1 that appeared in the January 2007 edition of your journal. It essentially corroborates our 2004 study on 27 examples of the same lesion that established the morphologically hybrid nature of tubulolobular carcinomas with an immunophenotype more similar to tubular carcinoma than lobular carcinoma (Wheeler et al).
2 When a tumor is being evaluated for expression of an antibody and the results are compared with those of another study, it is important to apply the same methodologies. As pointed out in one of our previous studies (Bratthauer et al), 3 the high-molecular weight cytokeratin clone 34bE12 is not by itself suitable for the distinction of classic lobular neoplasia from ductal or hybrid neoplastic lesions and that it is of value only when used in tandem with E-cadherin immunostains. This earlier report also pointed out that for immunohistochemical staining of 34bE12, a heat retrieval form of antigen recovery was used-not the proteolytic enzyme digestion performed in the study by Esposito et al. 1 Although it is possible that the subset of lobular, tubulolobular, and tubular carcinomas used in Esposito et al's 1 study may have reacted differently with 34bE12 compared to the cases we reported, comparisons are valid only when exactly the same methodologies are used. It would be of interest to repeat the high-molecular weight cytokeratin (34bE12) assay on Esposito et al's 1 tumor samples with a pH 6.0 heat retrieval pretreatment to see if the results are any different than those obtained using enzyme digestion. In reply: We thank Mr Bratthauer, Dr Wheeler and Dr Tavassoli for their comments on our article.
The methodology that we use for 34bE12 antibody is different from that used by Wheeler et al, 1 beginning with section thickness. We do not use 6 mm sections for any immunostaining procedure in contrast to the study by Wheeler et al. Indeed, it is not uncommon for a multitude of protocols to exist for any given antibody across laboratories.
The methodology that we use in our laboratory has been optimized and validated against tissues and controls with the Benchmark XT (Ventana Medical Systems, Tuscon, AZ, USA), and the results have been quite satisfactory in our diagnostic experience. We have not optimized 34bE12 antibody in our laboratory for detecting lobular carcinomas, because 34bE12 is an antibody that detects a highmolecular-weight cytokeratin that ultrastructurally correlates with the presence of tonofilaments. Tonofilaments are present in carcinomas of any duct derivation in addition to squamous cell carcinomas. 2 We detected 34bE12 in 50% of lobular carcinomas (10 cases examined) vs 80% in the paper by Wheeler et al (5 cases examined). The paper by Wheeler et al also clearly demonstrates that 34bE12 is not useful in the distinction of tubulolobular (93% positive) vs lobular carcinomas (80% positive). E-cadherin alone is a superior antibody for the distinction of ductal vs lobular phenotypes.
It was not the intent of our paper to discuss the usefulness of 34bE12 in making the diagnosis of lobular carcinoma. Rather, our goal was to demonstrate the ductal immunostaining patterns, specifically of E-cadherin and p120 catenin, both of which are biological markers for the E-cadherin/catenin complex. Ours is the first study to demonstrate the membrane-dominant ductal phenotype immunostaining pattern of p120 catenin in tubulolobular carcinomas. The cytoplasmic p120 catenin immunostaining pattern that we described in lobular neoplasia was absent in the tubulolobular group and present in the lobular carcinomas. P120 catenin and E-cadherin are equally sensitive and specific (100%) 3 and far superior to 34bE12 for the distinction of ductal vs lobular phenotypes. 
